The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.

about

Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines.

P2860

Q55397522-8DE831D2-4AB0-4D89-B887-D38B29169F53

P2860

The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.

Item

http://www.wikidata.org/entity/Q38694934

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The Phosphatidylinositol 3-kin ...... utic Target in Bladder Cancer.

@en

type

Item

label

The Phosphatidylinositol 3-kin ...... utic Target in Bladder Cancer.

@en

prefLabel

The Phosphatidylinositol 3-kin ...... utic Target in Bladder Cancer.

@en

P1476

The Phosphatidylinositol 3-Kin ...... eutic Target in Bladder Cancer

@en

P2093

Ai-Hong Ma

http://www.w3.org/2001/XMLSchema#string

Chong-Xian Pan

http://www.w3.org/2001/XMLSchema#string

Chuan-Liang Xu

http://www.w3.org/2001/XMLSchema#string

Clifford G Tepper

http://www.w3.org/2001/XMLSchema#string

Hongyong Zhang

http://www.w3.org/2001/XMLSchema#string

Jian-Ming Guo

http://www.w3.org/2001/XMLSchema#string

Paul T Henderson

http://www.w3.org/2001/XMLSchema#string

Ralph W deVere White

http://www.w3.org/2001/XMLSchema#string

Susan Airhart

http://www.w3.org/2001/XMLSchema#string

Tzu-Yin Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy

Mapping and quantifying mammalian transcriptomes by RNA-Seq

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Leukocyte-specific protein 1 targets the ERK/MAP kinase scaffold protein KSR and MEK1 and ERK2 to the actin cytoskeleton

PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics

Human box H/ACA pseudouridylation guide RNA machinery

Comprehensive molecular characterization of urothelial bladder carcinoma

Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation

P304

6580-6591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-17-0033

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shu-Xiong Zeng

P577

2017-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28808038

http://www.w3.org/2001/XMLSchema#string

P932

5668181

http://www.w3.org/2001/XMLSchema#string

The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.

about

P2860

P2860

The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932